Next-generation sequencing reveals mutations in RB1, CDK4 and TP53 that may promote chemo-resistance to palbociclib in ovarian cancer

Journal Name: Drug Metabolism and Personalized Therapy Issue: Ahead of print
Source: Drug Metabolism and Personalized Therapy - Category: Drugs & Pharmacology Source Type: research